Drug intelligence / Profile preview

Far Biotech tau aggregation inhibitor

Development stage: Preclinical
Lead developer: Far Biotech
Modality: Small Molecules

Overview

Far Biotech's tau aggregation inhibitor is a preclinical-stage small molecule discovered using the company's proprietary Quantum AI platform. It is designed to treat Alzheimer's disease and other neurodegenerative disorders by preventing or disrupting the pathological aggregation of tau proteins. Pathological tau aggregation is a key hallmark of neurodegeneration, leading to the formation of neurofibrillary tangles and subsequent neuronal dysfunction. These structurally novel leads are being developed in collaboration with the research partner Aragen.

Other names: Tau aggregation inhibitor (structurally novel leads)Far Biotech Tau small molecule

Targets

MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on Far Biotech tau aggregation inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Far Biotech tau aggregation inhibitor.

Explore the full profile